• Media type: E-Article
  • Title: Abstract 42: Platelet Polyphosphate Accelerates the Inhibition of Tissue Factor Pathway Inhibitor by Factor XIa
  • Contributor: Puy, Cristina; Gruber, András; Tucker, Erik I; Gailani, David; Smith, Stephanie A; Choi, Sharon H; Morrissey, James H; McCarty, Owen J
  • imprint: Ovid Technologies (Wolters Kluwer Health), 2015
  • Published in: Arteriosclerosis, Thrombosis, and Vascular Biology
  • Language: English
  • DOI: 10.1161/atvb.35.suppl_1.42
  • ISSN: 1079-5642; 1524-4636
  • Keywords: Cardiology and Cardiovascular Medicine
  • Origination:
  • Footnote:
  • Description: <jats:p> <jats:bold>Introduction:</jats:bold> Our group has recently identified that alpha tissue factor pathway inhibitor (TFPIα) can be neutralized by activated factor XI (FXIa), accelerating plasma clotting time and fibrin generation, although this reaction was slow and required relatively high concentrations of FXIa. Activated platelets secrete the anionic polymer polyphosphate (polyP), which potently accelerate the activation of FXI by thrombin and the activation of FV by FXIa. PolyP is also able to inhibit the anticoagulant effect of TFPIα in plasma but the mechanism for this reaction is still uncertain. We assessed the hypothesis that polyP of the size secreted by activated human platelets is cofactor for the inhibition of TFPIα by FXIa. </jats:p> <jats:p> <jats:bold>Methods:</jats:bold> To measure the binding of polyP to TFPI, biotinylated-polyP was added to TFPIα-coated wells. Binding was detected with HRP-streptavidin. Activated FX (FXa) inhibition by TFPIα was measured in the FXa-initiated clotting time of FX-depleted plasma. TFPIα inhibition of FXa generation by the tissue factor (TF)-FVIIa complex was measuring using a FXa chromogenic substrate. TFPIα was pretreated with FXIa in the absence or presence of polyP </jats:p> <jats:p> <jats:bold>Results:</jats:bold> We found that polyP was able to bind to TFPIα in a concentration-dependent manner. In the absence of polyP, the pretreatment of TFPIα (5 nM) with 1 nM FXIa for 1 hour abrogated the anticoagulant effect of TFPIα in the FXa-initiated clotting time of FX-depleted plasma. In the presence of polyP (10 μM), the pretreatment of TFPIα (5 nM) with 0.25 nM FXIa for 30 min was enough to completely abrogate the anticoagulant effect of TFPIα in plasma. Also, the presence of polyP potently accelerated the effect of FXIa to inhibit the capacity of TFPIα to block the generation of FX by the TF-FVIIa complex. </jats:p> <jats:p> <jats:bold>Conclusion:</jats:bold> Our study provides a novel molecular link between hemostatic activation of platelets and FXI. The results suggest that the hemostatic role of FXIa may be attributed not only to activation of FIX but also to promoting the extrinsic pathway of thrombin generation through inactivation of TFPIα by FXIa, which is significantly enhanced by the release and presence of activated platelet-derived polyphosphates. </jats:p>